ImmunityBio, Inc. — Director's Dealing 2024

Feb 3, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ImmunityBio, Inc. (IBRX)
CIK: 0001326110
Period of Report: 2024-01-31

Reporting Person: LAUER REGAN J (Chief Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-01-31	Common Stock	M	32872	—	Acquired	107804	Direct
2024-01-31	Common Stock	F	13470	$3.36	Disposed	94334	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-01-31	Restricted Stock Units	$	M	32872	Disposed		Common Stock (32872)	Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

F2: Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, fifty percent (50%) of the RSUs subject to the award vested on September 1, 2023 and the remaining fifty percent (50%) of the RSUs subject to the award vested on January 31, 2024.